ICIs augment T-cell mediated anti-tumor responses, most commonly via programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways (5). Here, CTLA4 is linked to neoplasm.